Moyamoya disease emerging as an immune-related angiopathy
- Author
- Caroline Asselman (UGent) , Dimitri Hemelsoet (UGent) , Denzel Eggermont (UGent) , Bart Dermaut (UGent) and Francis Impens (UGent)
- Organization
- Project
-
- Precisie-genomica in neurodegeneratieve hersenziekten: van patiënten tot kleine modelorganismen en afzonderlijke cellen
- Precision genomics in neurodegenerative brain disease: from patients to small model organisms and single cells
- Proteomics-based characterization of the protein interplay between pathogenic bacteria and their host.
- Proteomics-derived epitopes for dramatically improved anticancer and antibacterial vaccine development
- Abstract
- Moyamoya disease (MMD) is a rare cerebrovascular disorder with unknown etiology. MMD is characterized by progressive narrowing of arteries of the brain and the formation of a compensatory network of fragile vessels. Genetic studies have identified RNF213, also known as mysterin, as a susceptibility gene for MMD, but the low penetrance in genetically susceptible individuals suggests that a second hit is necessary to trigger disease onset. Recently, several molecular studies uncovered RNF213 as a key antimicrobial protein with important functions in the immune system. In addition, an increasing number of clinical reports describe the development of moyamoya angiopathy (MMA) asso-ciated with infection or autoimmune disorders. Together, this growing body of molecular and clinical evidence points towards immune-related responses as second hits to trigger MMD onset.
Downloads
-
1-s2.0-S1471491422002143-main.pdf
- full text (Published version)
- |
- open access
- |
- |
- 1.34 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8768234
- MLA
- Asselman, Caroline, et al. “Moyamoya Disease Emerging as an Immune-Related Angiopathy.” TRENDS IN MOLECULAR MEDICINE, vol. 28, no. 11, 2022, pp. 939–50, doi:10.1016/j.molmed.2022.08.009.
- APA
- Asselman, C., Hemelsoet, D., Eggermont, D., Dermaut, B., & Impens, F. (2022). Moyamoya disease emerging as an immune-related angiopathy. TRENDS IN MOLECULAR MEDICINE, 28(11), 939–950. https://doi.org/10.1016/j.molmed.2022.08.009
- Chicago author-date
- Asselman, Caroline, Dimitri Hemelsoet, Denzel Eggermont, Bart Dermaut, and Francis Impens. 2022. “Moyamoya Disease Emerging as an Immune-Related Angiopathy.” TRENDS IN MOLECULAR MEDICINE 28 (11): 939–50. https://doi.org/10.1016/j.molmed.2022.08.009.
- Chicago author-date (all authors)
- Asselman, Caroline, Dimitri Hemelsoet, Denzel Eggermont, Bart Dermaut, and Francis Impens. 2022. “Moyamoya Disease Emerging as an Immune-Related Angiopathy.” TRENDS IN MOLECULAR MEDICINE 28 (11): 939–950. doi:10.1016/j.molmed.2022.08.009.
- Vancouver
- 1.Asselman C, Hemelsoet D, Eggermont D, Dermaut B, Impens F. Moyamoya disease emerging as an immune-related angiopathy. TRENDS IN MOLECULAR MEDICINE. 2022;28(11):939–50.
- IEEE
- [1]C. Asselman, D. Hemelsoet, D. Eggermont, B. Dermaut, and F. Impens, “Moyamoya disease emerging as an immune-related angiopathy,” TRENDS IN MOLECULAR MEDICINE, vol. 28, no. 11, pp. 939–950, 2022.
@article{8768234,
abstract = {{Moyamoya disease (MMD) is a rare cerebrovascular disorder with unknown etiology. MMD is characterized by progressive narrowing of arteries of the brain and the formation of a compensatory network of fragile vessels. Genetic studies have identified RNF213, also known as mysterin, as a susceptibility gene for MMD, but the low penetrance in genetically susceptible individuals suggests that a second hit is necessary to trigger disease onset. Recently, several molecular studies uncovered RNF213 as a key antimicrobial protein with important functions in the immune system. In addition, an increasing number of clinical reports describe the development of moyamoya angiopathy (MMA) asso-ciated with infection or autoimmune disorders. Together, this growing body of molecular and clinical evidence points towards immune-related responses as second hits to trigger MMD onset.}},
author = {{Asselman, Caroline and Hemelsoet, Dimitri and Eggermont, Denzel and Dermaut, Bart and Impens, Francis}},
issn = {{1471-4914}},
journal = {{TRENDS IN MOLECULAR MEDICINE}},
language = {{eng}},
number = {{11}},
pages = {{939--950}},
title = {{Moyamoya disease emerging as an immune-related angiopathy}},
url = {{http://doi.org/10.1016/j.molmed.2022.08.009}},
volume = {{28}},
year = {{2022}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: